Skip to main content
. 2013 Mar 15;10(5):567–574. doi: 10.7150/ijms.5795

Figure 1.

Figure 1

Patients, adherence rates, and the prevalence of viral breakthrough in this study. ETV, entecavir; LAM, lamivudine.